Merck & Co Inc
NYSE: MRK
$100.98
+$1.73 (+1.7%)
Closing Price on January 13, 2025
MRK Articles
GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of HIV infection in adults. While Gilead has...
Published:
Last Updated:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday. There are many reports this morning! ADTRAN Inc. (NASDAQ: ADTN) Cut to...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. ...
Published:
Last Updated:
The three major US stock indexes opened lower this morning as markets have begun to reach the conclusion that this week’s Eurozone summit is not likely to resolve the continent’s financial...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Monday. ABB Ltd. (NYSE: ABB) Cut to Underweight at JPMorgan. Alaska Air Group...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday. Celgene Corporation (NASDAQ: CELG) Maintained Buy with target of $73.00...
Published:
Last Updated:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around this diabetes treatment...
Published:
Last Updated:
The 10-year Treasury hit yet another record low under 1.6% today and stocks are in the tank again due to poor economic data. Europe continues to face a meltdown and the hope is for a rate cut out...
Published:
Last Updated:
A stock market that sells off eight of nine days is not a good market. Even the Facebook IPO is being viewed as a one-off item rather than a systemic item which will make the market stronger. ...
Published:
Last Updated:
Blame whatever you want. A weaker U.S. economy, a weakening and flailing Europe, a move to socialism in France and Greece, a weaker BRIC and emerging market story, commodity prices and on and...
Published:
Last Updated:
Markets opened higher this morning following a lower-than-expected GDP growth estimate of 2.2%. That was weaker, but not awful (our coverage here). The consumer sentiment survey rose a couple of...
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.